Indaptus Therapeutics to be Acquired by 03 Life Sciences
Ticker: INDP · Form: 8-K · Filed: Mar 25, 2024 · CIK: 1857044
| Field | Detail |
|---|---|
| Company | Indaptus Therapeutics, INC. (INDP) |
| Form Type | 8-K |
| Filed Date | Mar 25, 2024 |
| Risk Level | medium |
| Pages | 4 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.01 |
| Sentiment | neutral |
Sentiment: neutral
Topics: acquisition, merger
TL;DR
Indaptus Therapeutics is getting bought by 03 Life Sciences, deal expected Q2 2024.
AI Summary
Indaptus Therapeutics, Inc. announced on March 25, 2024, that it has entered into a definitive agreement to be acquired by 03 Life Sciences. The transaction is expected to close in the second quarter of 2024, subject to customary closing conditions. This acquisition marks a significant development for Indaptus Therapeutics.
Why It Matters
This acquisition by 03 Life Sciences could lead to new developments or strategic shifts for Indaptus Therapeutics' pipeline and operations.
Risk Assessment
Risk Level: medium — Acquisition news can introduce volatility as market participants assess the deal terms and future prospects.
Key Players & Entities
- Indaptus Therapeutics, Inc. (company) — Company filing the report and being acquired
- 03 Life Sciences (company) — Acquiring company
- March 25, 2024 (date) — Date of the report and announcement
- second quarter of 2024 (date) — Expected closing period for the acquisition
FAQ
What is the primary purpose of this Form 8-K filing?
The primary purpose of this Form 8-K filing is to report the material event of Indaptus Therapeutics, Inc. entering into a definitive agreement to be acquired by 03 Life Sciences.
Who is acquiring Indaptus Therapeutics, Inc.?
Indaptus Therapeutics, Inc. is being acquired by 03 Life Sciences.
When is the acquisition expected to close?
The acquisition is expected to close in the second quarter of 2024.
What are the conditions for the acquisition to close?
The acquisition is subject to customary closing conditions.
What was Indaptus Therapeutics' former company name?
Indaptus Therapeutics' former company name was Intec Parent Inc., with a date of name change on April 14, 2021.
Filing Stats: 1,092 words · 4 min read · ~4 pages · Grade level 18.9 · Accepted 2024-03-25 08:31:43
Key Financial Figures
- $0.01 — nge on which registered Common Stock, $0.01 par value INDP Nasdaq Capital Mark
Filing Documents
- form8-k.htm (8-K) — 38KB
- 0001493152-24-011080.txt ( ) — 205KB
- indp-20240325.xsd (EX-101.SCH) — 3KB
- indp-20240325_lab.xml (EX-101.LAB) — 33KB
- indp-20240325_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: March 25, 2024 INDAPTUS THERAPEUTICS, INC. By: /s/ Nir Sassi Name: Nir Sassi Title: Chief Financial Officer